OncoTherapy Science, Inc. (JP:4564)

:4564

4564

OncoTherapy Science

RESEARCH TOOLSreports

Want to see JP:4564 full AI Analyst Report?

OncoTherapy Science (4564) Price & Analysis

2 Followers

4564 Stock Chart & Stats

¥21.00

-¥1.00(-4.17%)

At close: Jan 08 4:00 PM EST

¥21.00

-¥1.00(-4.17%)

Day’s Range― - ―

52-Week Range¥18.00 - ¥35.00

Previous CloseN/A

Volume4.29M

Average Volume (3M)39.41M

Market Cap

¥7.57B

Enterprise Value¥5.97B

Total Cash (Recent Filing)¥1.23B

Total Debt (Recent Filing)¥37.14M

Price to Earnings (P/E)―

Beta0.46

Next Earnings

Jan 29, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.03

Shares Outstanding398,643,700

10 Day Avg. Volume60,218,049

30 Day Avg. Volume39,409,347

Financial Highlights & Ratios

PEG Ratio0.67

Price to Book (P/B)3.22

Price to Sales (P/S)8.53

P/FCF Ratio-7.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Capital CushionZero reported debt and a material increase in equity provide a durable capital cushion that reduces immediate refinancing risk and preserves strategic optionality for R&D or partnerships. This balance-sheet strength helps extend runway relative to similarly loss-making peers, improving resilience over the next 2–6 months.

Improving Gross MarginsA move to slightly positive gross margins signals structural improvement in cost of goods or product mix, which can reduce the rate at which revenues translate into cash burn. If sustained, higher gross margins materially improve the economics of future product commercialization and support more efficient R&D spend allocation.

Focused Oncology R&D PlatformA clear, specialized focus on tumor-specific biology and immune-targeting therapeutics aligns the company with persistent structural demand in oncology and creates potential for high-value partnerships or licensing. Focused programs can concentrate scarce resources and increase the odds of meaningful clinical or commercial milestones over the medium term.

Bears Say

Chronic Negative Cash Flow / Cash BurnConsistently negative operating and free cash flow mean losses translate into real cash outflows rather than non-cash charges, forcing reliance on external funding. Over 2–6 months this elevates dilution and execution risk, constrains strategic investments, and makes timing of financing events a central operational consideration.

Ongoing Operating LossesOperating losses that approach the scale of revenue indicate fundamental unprofitability of current operations. This limits the company's ability to self-fund development, increases dependency on external capital, and raises the bar for achieving sustainable profitability even if revenue or margins improve modestly.

Volatile Revenue And Recent DeclineRevenue volatility and a recent year-over-year decline reduce forecasting visibility and impair planning for R&D and commercialization. For a biotech reliant on milestone timing and partnerships, unstable top-line trends weaken negotiating leverage and increase the probability of needing interim financing within a medium-term horizon.

4564 FAQ

What was OncoTherapy Science, Inc.’s price range in the past 12 months?

OncoTherapy Science, Inc. lowest stock price was ¥18.00 and its highest was ¥35.00 in the past 12 months.

What is OncoTherapy Science, Inc.’s market cap?

OncoTherapy Science, Inc.’s market cap is ¥7.57B.

When is OncoTherapy Science, Inc.’s upcoming earnings report date?

OncoTherapy Science, Inc.’s upcoming earnings report date is Jan 29, 2027 which is in 231 days.

How were OncoTherapy Science, Inc.’s earnings last quarter?

OncoTherapy Science, Inc. released its earnings results on Feb 06, 2026. The company reported -¥0.63 earnings per share for the quarter, missing the consensus estimate of N/A by -¥0.63.

Is OncoTherapy Science, Inc. overvalued?

According to Wall Street analysts OncoTherapy Science, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoTherapy Science, Inc. pay dividends?

OncoTherapy Science, Inc. does not currently pay dividends.

What is OncoTherapy Science, Inc.’s EPS estimate?

OncoTherapy Science, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoTherapy Science, Inc. have?

OncoTherapy Science, Inc. has 398,643,700 shares outstanding.

What happened to OncoTherapy Science, Inc.’s price movement after its last earnings report?

OncoTherapy Science, Inc. reported an EPS of -¥0.63 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of OncoTherapy Science, Inc.?

Currently, no hedge funds are holding shares in JP:4564

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoTherapy Science, Inc.

OncoTherapy Science, Inc. is a Japanese biotechnology firm dedicated to the discovery and advancement of innovative cancer treatments. Established in 2001 and headquartered in Kawasaki, Japan, the company's robust pipeline spans various therapeutic modalities. Among its small-molecule compounds, OTS167, an inhibitor of maternal embryonic leucine zipper kinase, is undergoing Phase I/II clinical trials for acute myeloid leukemia and Phase I trials for breast cancer. Another small-molecule asset, OTS964, targets T-LAK cell-originated protein kinase for a range of oncological conditions. The company's oncology peptide vaccine candidates include S-588410, which is in Phase III trials for esophageal cancer and Phase II for bladder cancer. S-488210 is progressing through Phase I/II clinical trials for head and neck cancer, while S-588210 is in Phase I for solid malignancies. In its antibody drug portfolio, OTSA101 is in Phase I clinical trials for synovial sarcoma. Notably, KHK6640, an anti-amyloid beta peptide antibody, is also in Phase I trials, targeting Alzheimer's disease – indicating a broader therapeutic scope. Beyond drug development, OncoTherapy Science, Inc. also provides specialized contract analysis services.